Latest Articles

Publication Date
Additional treatment option for endometriosis now available - New Zealand Doctor

Additional treatment option for endometriosis now available New Zealand Doctor

Published: Nov. 25, 2025, 11:37 a.m.
RG Pitampura Hospital Effectively Treats Rare Case Of Ruptured Bilateral Ovarian Endometriotic Cysts - BW Healthcare

RG Pitampura Hospital Effectively Treats Rare Case Of Ruptured Bilateral Ovarian Endometriotic Cysts BW Healthcare

Published: Nov. 25, 2025, 3:20 a.m.
Demand for Endometriosis Treatment in Japan | Global Market Analysis Report - 2035 - Future Market Insights

Demand for Endometriosis Treatment in Japan | Global Market Analysis Report - 2035 Future Market Insights

Published: Nov. 24, 2025, 8:01 a.m.
Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.

Mesonephric-like adenocarcinoma (MLA) is a rare and aggressive gynecologic malignancy that has only been recognized in the last decade. It arises in the endometrium, ovaries, and other extrauterine sites (often …

Published: Nov. 24, 2025, midnight
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis.

[This corrects the article DOI: 10.3389/fimmu.2021.641206.].

Published: Nov. 24, 2025, midnight
Oxidative Stress-Telomere Axis in IVF: Molecular Mechanisms, Biomarkers, and Clinical Translation.

The reduction in oocyte competence and ovarian reserve coincides with reproductive ageing; nevertheless, the molecular mechanisms underlying this phenomenon remain poorly understood. Our testable mechanistic hypothesis is that the oxidative …

Published: Nov. 24, 2025, midnight
Umbilical Endometriosis: A Case Report.

Endometriosis is characterized by the ectopic presence of endometrial tissue outside the uterus. When this tissue appears in regions beyond the reproductive organs, it is referred to as extragenital endometriosis. …

Published: Nov. 24, 2025, midnight
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight
Bidirectional Mendelian randomization and cross-sectional study reveal depression as a causal risk factor for endometriosis.

Endometriosis (EMs) and depression are both common conditions that have a significant negative impact on quality of life. However, it is still unclear about the relationship between them. The study …

Published: Nov. 21, 2025, midnight
The Effects of Emotional Freedom Technique on Pelvic Pain and Quality of Life in Women Diagnosed with Endometriosis: A Randomized Controlled Trial.

Objective: The primary goal of treatment for endometriosis (EMS), where pelvic pain is the most significant symptom, is the symptom alleviation. Medical treatment is typically employed until menopause or until …

Published: Nov. 21, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!